Cardiac troponin (cTn) biomarkers are the gold standard in myocardial infarction (MI) diagnosis, leading healthcare professionals to use cTn diagnostics. In addition, a rising number of patients visit emergency departments (EDs) with cardiac complaints, increasing ED demand for kits that can rapidly rule MI in or out. Both factors serve as significant drivers of the cTn diagnostics market.
Hospitals and clinical laboratories adopt high-sensitivity (hs) assays because of their ability to detect troponin in lower concentrations. The point-of-care testing (POCT) of cTn grows rapidly due to its rising applications in EDs and remote locations. POCT can provide rapid results in a shorter period than lab-based tests. In addition, companies such as QuidelOrtho and Siemens Healthineers have developed high-sensitivity POCT cTn assays that provide accurate results within a few minutes.
In this report, the analyst overviews the cTn diagnostics market and includes troponin I and troponin T. Our testing locations are independent laboratories, physicians' offices, urgent care and nursing facilities, inpatient hospitals, and emergency rooms. The study covers sensitive and hs-cTn tests.
The report also includes the following:
Market size by revenue, covering historic and forecast data by segment (lab-based tests and POCT) and region (North America, Europe, Asia-Pacific, and the rest of the world)
Challenges and drivers
Competitive landscape, including company market share for lab-based tests and POCT
Future trends and growth opportunities for stakeholders
North America is the leading region in the cTn diagnostics market, with hospitals and laboratories shifting toward high-sensitivity assays following approval from the United States Food and Drug Administration in 2017. The analyst's research shows high consolidation in the cTn diagnostics market, with players such as Abbot, Roche, and Siemens Healthineers dominating. New players are entering this market, especially in the POCT segment.
Key Topics Covered:
1. Strategic Imperatives
Why is it Increasingly Difficult to Grow?
The Strategic Imperative
The Impact of the Top 3 Strategic Imperatives on the Cardiac Troponin (cTn) Diagnostics Industry
Growth Opportunities Fuel the Growth Pipeline Engine
About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Surgeon's Advisor is proud to announce a strategic partnership with SEO software provider BrightLocal. The BrightLocal Partner Program provides agencies with powerful marketing tools to give clients a competitive edge when it comes to enhancing...
Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat R/R AML PopulationsTP53MUT CR/CRh = 20% ? RASMUT...
Product: IQF Whole Raspberries, IQF Antioxidant Blend
Issue: Food - Microbial Contamination - Norovirus
Distribution: New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Quebec
See the affected products and product photos for this recall...
Product: Lupini Beans
Issue: Food - Microbial Contamination - Clostridium botulinum
Distribution: Quebec
See the affected products and product photos for this recall
SOURCE Canadian Food Inspection Agency (CFIA)
The hygiene and health company Essity divests its operations in Russia. Essity has signed an agreement with a buyer and the transaction has now been approved by the Russian authorities. The transaction is expected to be finalized during the second...
BioArctic AB's (publ) partner Eisai announced today that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai's Phase 3 Clarity AD clinical...